Cargando…

Deep Immune Profiling of Multiple Myeloma at Diagnosis and under Lenalidomide Maintenance Therapy

SIMPLE SUMMARY: Currently, multiple myeloma is mostly an incurable disease. Given the poor survival and frequent disease relapses, there is an urgent need for new treatment approaches and patient stratification. In an attempt to predict response to treatment, we comprehensively analyzed the immune p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luoma, Sini, Sergeev, Philipp, Javarappa, Komal Kumar, Öhman, Tiina J., Varjosalo, Markku, Säily, Marjaana, Anttila, Pekka, Sankelo, Marja, Partanen, Anu, Nihtinen, Anne, Heckman, Caroline A., Silvennoinen, Raija
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10177338/ https://www.ncbi.nlm.nih.gov/pubmed/37174069 http://dx.doi.org/10.3390/cancers15092604

Ejemplares similares

RVD induction and autologous stem cell transplantation followed by lenalidomide maintenance in newly diagnosed multiple myeloma: a phase 2 study of the Finnish Myeloma Group
por: Luoma, Sini, et al.
Publicado: (2019)

P898: A PROSPECTIVE PHASE 2 STUDY TO ASSESS MINIMAL RESIDUAL DISEASE AFTER IXAZOMIB, LENALIDOMIDE, DEXAMETHASONE (IRD) TREATMENT FOR NEWLY DIAGNOSED TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS
por: Silvennoinen, Raija, et al.
Publicado: (2023)

Long-term outcome after allogeneic stem cell transplantation in multiple myeloma
por: Luoma, Sini, et al.
Publicado: (2021)

A germline exome analysis reveals harmful POT1 variants in multiple myeloma patients and families
por: Hakkarainen, Marja, et al.
Publicado: (2022)

Mobilization Strategies in Myeloma Patients Intended for Autologous Hematopoietic Cell Transplantation
por: Jantunen, Esa, et al.
Publicado: (2023)

Prognostic significance of esterase gene expression in multiple myeloma
por: Kumari, Romika, et al.
Publicado: (2021)

Next generation proteomics with drug sensitivity screening identifies sub-clones informing therapeutic and drug development strategies for multiple myeloma patients
por: Tierney, Ciara, et al.
Publicado: (2021)

Molecular pathogenesis of rhegmatogenous retinal detachment
por: Öhman, Tiina, et al.
Publicado: (2021)

A randomized phase II study of stem cell mobilization with cyclophosphamide+G-CSF or G-CSF alone after lenalidomide-based induction in multiple myeloma
por: Silvennoinen, R, et al.
Publicado: (2016)

Aminopeptidase Expression in Multiple Myeloma Associates with Disease Progression and Sensitivity to Melflufen
por: Miettinen, Juho J., et al.
Publicado: (2021)

Identification of precision treatment strategies for relapsed/refractory multiple myeloma by functional drug sensitivity testing
por: Majumder, Muntasir Mamun, et al.
Publicado: (2017)

Real-world treatment outcomes in multiple myeloma: Multicenter registry results from Finland 2009-2013
por: Remes, Kari, et al.
Publicado: (2018)

S100 Calcium Binding Protein Family Members Associate With Poor Patient Outcome and Response to Proteasome Inhibition in Multiple Myeloma
por: Liu, Minxia, et al.
Publicado: (2021)

Systems pathology analysis identifies neurodegenerative nature of age‐related vitreoretinal interface diseases
por: Öhman, Tiina, et al.
Publicado: (2018)

Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myeloma
por: Lund, Johan, et al.
Publicado: (2018)

A cluster of Candida krusei infections in a haematological unit
por: Hautala, Timo, et al.
Publicado: (2007)

Skeletal muscle proteomes reveal downregulation of mitochondrial proteins in transition from prediabetes into type 2 diabetes
por: Öhman, Tiina, et al.
Publicado: (2021)

Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment
por: Dimopoulos, M A, et al.
Publicado: (2017)

Lenalidomide for the treatment of relapsed and refractory multiple myeloma
por: van de Donk, Niels WCJ, et al.
Publicado: (2012)

Lenalidomide in the Treatment of Lymphoproliferative Disorders and Multiple Myeloma
por: Liberati, Anna Marina, et al.
Publicado: (2013)

Physical and functional interactome atlas of human receptor tyrosine kinases
por: Salokas, Kari, et al.
Publicado: (2022)

Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens
por: Botta, Cirino, et al.
Publicado: (2021)

An AP-MS- and BioID-compatible MAC-tag enables comprehensive mapping of protein interactions and subcellular localizations
por: Liu, Xiaonan, et al.
Publicado: (2018)

Safety and Efficacy of Lenalidomide in Relapsed or Refractory Multiple Myeloma
por: Alegre, Adrian, et al.
Publicado: (2011)

How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma
por: de Arriba de la Fuente, Felipe, et al.
Publicado: (2022)

SUMOylation inhibition enhances multiple myeloma sensitivity to lenalidomide
por: Du, Li, et al.
Publicado: (2022)

Air Model for Electric Circuit
por: SÄILY, Markku
Publicado: (2000)

The Impact of ETV6-NTRK3 Oncogenic Gene Fusions on Molecular and Signaling Pathway Alterations
por: Kinnunen, Matias, et al.
Publicado: (2023)

Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX
por: Dimopoulos, Meletios A., et al.
Publicado: (2018)

Ixazomib combined with lenalidomide and dexamethasone chemotherapy for newly diagnosed multiple myeloma in China—Compared with bortezomib/lenalidomide/dexamethasone
por: Huo, Zhongjun, et al.
Publicado: (2022)

A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma
por: Hideshima, Teru, et al.
Publicado: (2008)

Activation of Coagulation by Lenalidomide-Based Regimens for the Treatment of Multiple Myeloma
por: Isozumi, Yu, et al.
Publicado: (2013)

Characteristics of exceptional responders to lenalidomide-based therapy in multiple myeloma
por: Vu, T, et al.
Publicado: (2015)

Prognostic impact of Ikaros expression in lenalidomide-treated multiple myeloma
por: Krönke, Jan, et al.
Publicado: (2017)

Extrapyramidal Symptoms with Administration of Lenalidomide Maintenance Therapy for Multiple Myeloma
por: Sagar, FNU, et al.
Publicado: (2018)

Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide
por: Moreau, Philippe, et al.
Publicado: (2019)

Pharmacokinetics and bioequivalence evaluation of lenalidomide in Chinese patients with multiple myeloma
por: Gao, Tiantao, et al.
Publicado: (2022)

Cost-Effectiveness of Post-Autotransplant Lenalidomide in Persons with Multiple Myeloma
por: Marchetti, Monia, et al.
Publicado: (2021)

AT-101 Enhances the Antitumor Activity of Lenalidomide in Patients with Multiple Myeloma
por: Ailawadhi, Sikander, et al.
Publicado: (2023)

Lenalidomide-Induced Diffuse Alveolar Hemorrhage in Patient With Multiple Myeloma
por: Qanash, Sultan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ihe9gkb0ta9slqq6egoi541b9o